Comparison of Oncotype Dx (ODx) 21-gene recurrence score (RS) in African American (AA) and Caucasian (C) patients with hormone receptor-positive (HR+), HER2-negative (HER2-), lymph node-negative (LNN) breast cancer (BC)

被引：0
|
作者：
Kabaker, K. B.
Canar, J.
Rao, R. D.
Cobleigh, M. A.
机构：
[1] Rush Univ, Med Ctr, Chicago, IL 60612 USA
[2] Edward Hines Jr VA Hosp, Hines, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.620
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
620
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The clinical impact of NOLUS in unresectable/metastatic hormone receptor-positive (HR+)/HER2-negative breast cancer
    Tajiri, Wakako
    Nakamura, Yoshiaki
    Kawasaki, Junji
    Koi, Yumiko
    Akiyoshi, Sayuri
    Koga, Chinami
    Tokunaga, Eriko
    CANCER RESEARCH, 2024, 84 (09)
  • [32] The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?
    Aapro, Matti
    De Laurentiis, Michelino
    Rea, Dan
    Bargallo Rocha, Juan Enrique
    Elizalde, Roberto
    Landherr, Laszlo
    Linderholm, Barbro
    Mamounas, Eleftherios
    Markopoulos, Christos
    Neven, Patrick
    Petrovsky, Alexander
    Rouzier, Roman
    Smit, Vincent
    Svedman, Christer
    Schneider, Daniel
    Thomssen, Christoph
    Martin, Miguel
    BREAST, 2017, 33 : 191 - 199
  • [33] Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer
    Poorvu, Philip D.
    Gelber, Shari, I
    Rosenberg, Shoshana M.
    Ruddy, Kathryn J.
    Tamimi, Rulla M.
    Collins, Laura C.
    Peppercorn, Jeffrey
    Schapira, Lidia
    Borges, Virginia F.
    Come, Steven E.
    Warner, Ellen
    Jakubowski, Debbie M.
    Russell, Christy
    Winer, Eric P.
    Partridge, Ann H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (07) : 725 - +
  • [34] Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer
    Chae, Eun Young
    Moon, Woo Kyung
    Kim, Hak Hee
    Kim, Won Hwa
    Cha, Joo Hee
    Shin, Hee Jung
    Choi, Woo Jung
    Han, Wonshik
    Noh, Dong-Young
    Lee, Sae Byul
    Ahn, Sei Hyun
    PLOS ONE, 2016, 11 (06):
  • [35] TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.
    Sparano, Joseph A.
    Gray, Robert James
    Wood, William C.
    Makower, Della F.
    Lively, Tracy G.
    Saphner, Thomas James
    Keane, Maccon M.
    Gomez, Henry Leonidas
    Reddy, Pavan S.
    Goggins, Timothy F.
    Mayer, Ingrid A.
    Toppmeyer, Deborah
    Brufsky, Adam
    Goetz, Matthew P.
    Hayes, Daniel F.
    Dees, Elizabeth Claire
    Pritchard, Kathleen I.
    Geyer, Charles E.
    Olson, John A.
    Sledge, George W.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (18)
  • [36] Oncotype DX Breast Recurrence Score Distribution and Chemotherapy Benefit Among Women of Different Age Groups With HR-Positive, HER2-Negative, Node-Negative Breast Cancer in the SEER Database
    Cheng, Ran
    Kong, Xiangyi
    Wang, Xiangyu
    Fang, Yi
    Wang, Jing
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [37] What Is the Optimal Model to Estimate the Benefits of Chemotherapy in Patients With Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer?
    Ando, Kenju
    Shimomura, Akihiko
    Yoshimura, Kenichi
    Kawamura, Yukino
    Shimizu, Chikako
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (17) : 1946 - +
  • [38] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC)
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A.
    Yap, Y. S.
    Sonke, G. S.
    Paluch-Shimon, S.
    Campone, M.
    Blackwell, K.
    Andre, F.
    Winer, E. P.
    Janni, W.
    Verma, S.
    Conte, P.
    Arteaga, C. L.
    Cameron, D.
    Xuan, F.
    Souami, F.
    Miller, M.
    Germa, C.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [39] Validation of the 21-Gene Recurrence Score Assay in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer and 0 to 3 Positive Lymph Nodes: Risk Pattern and Outcomes on a Community Level
    Braun, Michael
    Kriegmair, Antonia
    Szeterlak, Nina
    Andrulat, Anne
    Schrodi, Simone
    Kriner, Monika
    Hanusch, Claus
    Hamann, Moritz
    Stoetzer, Oliver
    Poelcher, Martin
    BREAST CARE, 2022, 17 (03) : 288 - 295
  • [40] Ribociclib (RIB) plus endocrine therapy (ET) in Japanese women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC)
    Masuda, N.
    Noguchi, S.
    Ishikawa, T.
    Aruga, T.
    Kim, S. J.
    Toyama, T.
    Saeki, T.
    Saito, M.
    Yamanaka, T.
    Watanabe, J.
    Nakamura, S.
    Takahashi, M.
    Inoue, K.
    Gounaris, I.
    Han, Y.
    Samant, T. S.
    Gazdoiu, M.
    Ito, Y.
    ANNALS OF ONCOLOGY, 2018, 29
12345